NCT00941863 - Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

April 30, 2008

Conditions

Carcinoma

Interventions

DRUG

Sorafenib 100 mg (50-mg tablet)

Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)

DRUG

Sorafenib 200 mg (50-mg tablet)

Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)

DRUG

Sorafenib 400 mg (50-mg tablet)

Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)

DRUG

Sorafenib 400 mg (200-mg tablet)

Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)

DRUG

Sorafenib 400 mg (Expansion)

Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion

Trial Locations (3)

Philadelphia

Nashville

Madison